Verastem (VSTM)

Why Revenue Could Explode

1. 01Clinical trial data readouts for avutometinib/defactinib combination in LGSOC (primary endpoint: progression-free survival)
2. 02FDA regulatory interactions including breakthrough therapy designation status, pre-NDA meetings, and approval timeline guidance
3. 03Capital raises and cash runway extensions - dilution events typically pressure stock while runway extensions provide relief
4. 04Partnership announcements or licensing deals with major pharmaceutical companies for commercialization rights
5. 05Competitive clinical data from rival RAF/MEK or FAK inhibitor programs in similar indications

VSTM Chart

My Notes

• growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical/regulatory catalysts.
• Rising interest rates create significant headwinds for pre-revenue biotechs through multiple channels: (1) discount rate impact on NPV…
• Watch on earnings: Cash and short-term investments balance with quarterly burn rate trend, Clinical trial enrollment velocity and patient retention rates for pivotal LGSOC study, Objective response rate (ORR) and progression-free survival (PFS) data versus historical LGSOC benchmarks (6-9 month median PFS).